Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Emicizumab by Chugai Pharmaceutical for Von Willebrand Disease (vWD): Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase I for Von Willebrand Disease (vWD). According to...
Emicizumab by Chugai Pharmaceutical for Acquired Hemophilia A: Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Acquired Hemophilia A. According to GlobalData,...
Emicizumab by Chugai Pharmaceutical for Acquired Hemophilia A: Likelihood of Approval
Emicizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Acquired Hemophilia A. According to GlobalData,...